AMRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-07), Amarin's current share price is $0.673. Amarin's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.02. Amarin's Cyclically Adjusted PS Ratio for today is 0.66.
The historical rank and industry rank for Amarin's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Amarin's highest Cyclically Adjusted PS Ratio was 47.65. The lowest was 0.62. And the median was 7.04.
AMRN's Cyclically Adjusted PS Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Amarin's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.138. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.02 for the trailing ten years ended in Mar. 2024.
The historical data trend for Amarin's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amarin Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 1.57 | 1.21 | 0.92 | 0.86 | 0.87 |
For the Drug Manufacturers - General subindustry, Amarin's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Amarin's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Amarin's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Amarin's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 0.673 | / | 1.02 | |
= | 0.66 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amarin's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Amarin's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.138 | / | 120.9901 | * | 120.9901 | |
= | 0.138 |
Current CPI (Mar. 2024) = 120.9901.
Amarin Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.061 | 100.773 | 0.073 |
201409 | 0.081 | 100.474 | 0.098 |
201412 | 0.094 | 99.576 | 0.114 |
201503 | 0.091 | 99.975 | 0.110 |
201506 | 0.098 | 100.573 | 0.118 |
201509 | 0.117 | 100.274 | 0.141 |
201512 | 0.145 | 99.676 | 0.176 |
201603 | 0.139 | 99.676 | 0.169 |
201606 | 0.179 | 101.072 | 0.214 |
201609 | 0.157 | 100.274 | 0.189 |
201612 | 0.144 | 99.676 | 0.175 |
201703 | 0.128 | 100.374 | 0.154 |
201706 | 0.167 | 100.673 | 0.201 |
201709 | 0.175 | 100.474 | 0.211 |
201712 | 0.199 | 100.075 | 0.241 |
201803 | 0.154 | 100.573 | 0.185 |
201806 | 0.179 | 101.072 | 0.214 |
201809 | 0.187 | 101.371 | 0.223 |
201812 | 0.246 | 100.773 | 0.295 |
201903 | 0.223 | 101.670 | 0.265 |
201906 | 0.305 | 102.168 | 0.361 |
201909 | 0.320 | 102.268 | 0.379 |
201912 | 0.399 | 102.068 | 0.473 |
202003 | 0.429 | 102.367 | 0.507 |
202006 | 0.339 | 101.769 | 0.403 |
202009 | 0.402 | 101.072 | 0.481 |
202012 | 0.428 | 101.072 | 0.512 |
202103 | 0.360 | 102.367 | 0.425 |
202106 | 0.385 | 103.364 | 0.451 |
202109 | 0.358 | 104.859 | 0.413 |
202112 | 0.342 | 106.653 | 0.388 |
202203 | 0.238 | 109.245 | 0.264 |
202206 | 0.237 | 112.779 | 0.254 |
202209 | 0.222 | 113.504 | 0.237 |
202212 | 0.223 | 115.436 | 0.234 |
202303 | 0.212 | 117.609 | 0.218 |
202306 | 0.197 | 119.662 | 0.199 |
202309 | 0.162 | 120.749 | 0.162 |
202312 | 0.183 | 120.749 | 0.183 |
202403 | 0.138 | 120.990 | 0.138 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Amarin's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Steven B Ketchum | officer: Chief Scientific Officer | 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303 |
Patrick Holt | director, officer: See Remarks | C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Oliver O'connor | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Paul Cohen | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Diane E. Sullivan | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Louis Iii Sterling | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Keith Horn | director | 204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701 |
Patrice Eadon Bonfiglio | director | 488 HAVILAND ROAD, STAMFORD CT 06903 |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Thomas Charles Reilly | officer: SVP and CFO | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902 |
Aaron Berg | officer: EVP, President US | C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921 |
Karim Mikhail | director, officer: President and CEO | C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807 |
Olsen Per Wold | director | C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Murray Stewart | director | C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
From GuruFocus
By Marketwired • 08-07-2023
By sperokesalga sperokesalga • 05-12-2023
By Business Wire Business Wire • 02-28-2023
By Business Wire Business Wire • 02-21-2023
By GuruFocus Research • 11-01-2023
By PRNewswire • 07-19-2023
By Business Wire Business Wire • 02-27-2023
By sperokesalga sperokesalga • 02-22-2023
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 10-19-2023